Droplet Digital PCR

Many of the studies used liquid biopsy based on ddPCR technology to predict treatment response or track disease progression

With Bio-Rad's expertise, EMBL aims to expand its training portfolio of innovative methodologies for young scientists

First commercially available droplet digital PCR solution for detecting pathogenic STEC

New solution empowers scientists to precisely evaluate the efficiency of their experiment in less time and at lower cost than with any other method

Droplet Digital™ PCR–based assay quickly and cost-effectively assesses genome-editing events

Digital PCR (dPCR) is a gene amplification method particularly suited to detecting and quantifying rare genes.

Stephen Bustin, PhD talks about the persisting problem of lack of transparency and reliability in current PCR data.

Food testing labs have traditionally used conventional PCR and quantitative real-time PCR (qPCR) to detect the presence of genetically modified organisms (GMOs) in food and feed. When quantification is required, GMO content in these samples is expressed in relative terms as the ratio of the quantity of the transgene, which is the nucleic acid fragment introduced in the host genome, to that of an endogene, a gene normally found in the host genome. 

Since its introduction in 2011, Bio-Rad Laboratory’s Droplet Digital PCR (ddPCR™) technology has demonstrated the potential to be a transformative technology, particularly in clinical applications. At the second annual CHI Digital PCR Conference in San Diego, CA, Oct. 7–9, 2013, 12 scientists using Bio-Rad’s Droplet Digital PCR systems will highlight ddPCR applications that have advanced their research.

Basic research and clinical research labs have long relied on real-time PCR (qPCR) for its speed, sensitivity, specificity and ease-of-use. Common applications include gene expression analysis, mutation detection and identification of copy number variation to better understand inherited disorders, cancer and infectious disease.